Big Data & Analytics for Pharma

Gain greater insight through data science

November 5 & 6, 2014,Sofitel,

Philadelphia, PA

Speakers Include

Companies Presenting

• Director, Analytics, Merck

• Director Analytics, , Pfizer

• Principal Scientist, AstraZeneca

• Principal Research Scientist, Janssen R&D

• Principal Scientist, Bristol-Myers Squibb

• Senior Director, Analytics, Express Scripts

• Senior Director, IT, Medtronic

• Associate Director, Data Science, Abbvie

• Director, Transformational Management, Dr.

Reddy’s

• Computational Biologist Specialist, J&J

• Director, Multi-Channel Analytics, GSK

• Senior Director, Business Analytics, Allergan

• Snr. Manager, IT R&D Informatics, Momenta

• Lead, Business Analyst, Biogen

• VP, IT Business Partnering, GSK

• Senior Director, R&D Informatics,

AstraZeneca

• Head of IT Planning, Celgene

• Senior Investigator, GSK

• Scientist II, Berg Pharma

• Associate Director, Customer Interaction

Hub, Bristol-Myers Squibb

Who Will You Meet There is no question that IE. provides the gold standard events in the industry and will connect you with decision makers within the analytics industry. You will be meeting senior level executives from major corporations and innovative small to medium size companies.

Job Title Of Attendees

President/Principal

SVP/VP

C-Level

Snr. Director/Director

Global Head/ Head

Snr. Manager/Manager

Academic (1%)

78%

1000+ Employees300-999 Employees50-299 EmployeesLess than 49 Employees

Company Size Of Attendees

8%

11%

25%56% 81%Attendees are

companies with at least 300

employees

3%

21%

12%

42%

13%

8%

Attendees are at Director level or above

Delegates Include• Senior VP, Forest Laboratories

• Senior Director, CSL Behring

• Vice President, Sanofi Pasteur

• Head of Business Analytics, AstraZeneca

• Director, Analytics, Pfizer

• Vice President, Business Intelligence, Abbvie

The Big Data & Analytics for Pharma Summit brings together thought-leaders from the industry for an event acclaimed for its interactive sessions and high-level speakers. As many organisations are now gathering more data on patients than ever before, they are able to achieve 360 degree view on the market and view patterns in their data. This presents both a challenge and opportunity as organisations must gain actionable results in order to succeed. Bringing together the decision makers and

leaders from within the industry, this event will focus on the challenges specific to Pharmaceutical companies surrounding data analytics, insight and data visualisation, as well as the benefits of using analytics and analysis in a rapidly evolving and challenging market. Illustrated with industry case studies as well as informative panels and breakout sessions, this summit promises to be the must attend event for data scientists working within Pharma.

About the Summit

Speakers Information

Cathy is an Information Strategist in the Clinical Informatics & Innovations Group at Pfizer.  She has been with Pfizer for 9 years and has focused extensively on data integration, discoverability, and search in order to enable decision support in the Drug Discovery and Development Process.  For the last two  years, she has been working a project at Pfizer to establish a clinical data strategy to enable precision medicine research from very early drug discovery through patient selection in the clinical trials process. 

The 3R’s of Clinical Data in a Humanizing Drug Discovery World: Re-Use, Re-Analyze, Reveal New Science

Recognizing that large pharmaceutical companies have run thousands of clinical studies, there is a significant opportunity to capitalize on the science that can be obtained from the results of the studies alone. This session will explore three case studies demonstrating how clinical data is being re-used for exploratory research, some of the key challenges we face in making the most relevant data discoverable for scientific analytics, and how we might enable this type of research in a more efficient and automated manner than is possible today.

Catherine Marshall Director, Information Strategy & AnalyticsPfizer

Laura leads a newly reconfigured team focused on providing clinical trial operational data back to the organization.   Internal customers range from trial team members who manage ongoing tr ials to senior management who digest the various analyses to understand the impact of process improvement initiatives and identify areas for focus.   Laura spent most of her career as a consumer of information– from CRA to Therapeutic Area Clinical Operational Lead - and is able to use that experience in guiding new data analyses and interactive tool development. 

Laura GaluchieDirector, Clinical Performance, Analytics & InnovationMerck & Co.

Using Data to Help Guide Process & Efficiency Improvements

Teams of clinicians and statisticians apply a multitude of tools for real-time review and robust analysis of patient data generated from Clinical trials.     What about the operational data which is generated?   Is it analyzed and dissected as thoroughly? Are we maximizing the potential business value from our data?    When operational data is visible real-time and in an intuitive manner, it enables Clinical colleagues to be more productive, separate content from process,   and to quickly see areas to target for efficiencies. 

Speakers Information

David Tomala is Senior Director of Advanced Analytics at Express Scripts Inc., one of the nation's largest Prescription Benefit Manager. In this role he is charged with applying quantitative methods to advance Express Scripts's

David TomalaSenior Director, Advanced AnalyticsExpress Scripts

understanding of the consumer. Among Dave's responsibilities are the quantitative assessment of tests, the deve lopment and pract ica l app l i cat ion of segmentation, predictive models and other data-mined insights. His team's work on predicting adherence to medications has been featured in the Wall Street Journal. Prior to joining Express Scripts, he spent 10 years in various quantitative roles in financial services including investment banking, mortgage and credit card products.

Peter Gargalovic holds Principle Scientist position in Cardiovascular Drug Discovery, R&D, at Bristol-Myers Squibb, where he leads drug discovery project teams through phases of initial therapeutic target selection up to transition to clinical evaluation. He has extensive disease & drug discovery expertise and brings unique experience applying novel systems genetics approaches to large pre-clinical and clinical data sets to aid target & biomarker identification.  Prior to his current role, Peter was a clinical biomarker project leader in the Dept. of Clinical Discovery at BMS. He received his PhD at UNT-Health Science Center at Fort Worth, and completed his fellowship training at UCLA in the area of cardiovascular disease genetics.   

System Genetics - Integrating Complex Data

Recent rapid evolution of analytical & genomic methodologies, combined with the higher-throughput and lower cost led to an unprecedented access to large genomic and phenotypic data across the clinical and pre-clinical studies. A major challenge facing today R&D is the implementation of effective ways to leverage these large data sets and provide guidance for drug discovery and development. Systems genetics approaches are emerging as novel “cutting edge” tools to interrogate complex disease population data. This presentation will review the concepts and highlight specific examples of their application to drug discovery.

Peter Gargalovic Principal Scientist Bristol-Myers Squibb

Xia currently holds a principle scientist position at Biomedical Informatics group within the AstraZeneca Global Medicines Development (GMD) organization. Xia has track record of successfully applying novel biomedical informatics solutions to support clinical patient safety in translational safety analysis and predictive safety. Prior to stepping into the clinical domain, Xia was with the AstraZeneca Central Nervous System (CNS) Discovery in the areas of informatics and computational modeling to support early drug discovery in lead identification and lead optimization. Recently Xia contributes to Informatics efforts in Real World Evidence studies to support epidemiology, health economics and outcome, comparative effectiveness and marketing research. Xia holds a Ph.D. in computational chemistry and has extensive training in broad areas of Informatics.

Use of Graphical Query and Visual Analyses to Gain Insight from the Real World Data

This talk relates the experience at AstraZeneca in building interactive graphical database queries and visual analyses that allow researchers faster and better access to real world heath data to answer translational safety and observational research questions. Through cases studies we will illustrate how safety physicians and epidemiologists can use a graphical query language on a collaborative data exploration platform to build and execute complex queries and patients cohorts from real world data. The retrieved data sets can be automatically fed into visualization applications to achieve more intuitive interpretation of results through interactive visual analyses.

Xia WangPrincipal Scientist AstraZeneca

Speakers Information

A certified Master Black Belt and Change Agent, Barney has over 12 years of experience executing process improvement strategies for shared service organizations. He currently manages realization of the analytics project portfolio and performance optimization activities for Merck’s Shared Business Services (SBS) organization. In

Barnaby FountainDirector, Business AnalyticsMerck

this role, he manages our analytics return on investment, designs and facilitates Rapid Results workshops, and advances continuous improvement skills in shared services.   Since the formation of SBS in 2007, Barney has led the global Lean Six Sigma implementation.   Prior to joining Merck, Barney managed process improvement strategies in Honeywell's Global Business Services organization as a Black Belt and IT Program Manager.

Dr. Chris Huang is a Principal Scientist at Janssen Research and Development, LLC.   He earned his Ph.D. in Genetics from a joint program between Cold Spring Harbor Laboratory and the State University of New York at Stony Brook.  He then completed a postdoctoral training in genetic epidemiology at Harvard Medical School and Massachusetts General Hospital.   At the peak of human genome sequencing era, he joined Pangea Systems (aka DoubleTwist, Inc), one of pioneers of genomics database and analytical tools.   Since joining Johnson & Johnson in 2001, Dr. Huang has applied cutting-edge technologies such as OMICs and NGS to drug target discovery, biomarker discovery and development.

Big Data Experiment - Lesson Learned from a Whole Genome Sequencing Project of a Large RA Cohort

Recent advances in DNA sequencing technologies have increased the efficiency and reduced the cost of sequencing, leading to an explosion of high-quality data.  However, DNA sequence reads have limited biological utility without relevant downstream processing and analysis.   While the tools for performing these steps have improved, processing a whole genome from reads to variants, and from variants to biological insights, remains an expensive and time-consuming aspects of any sequencing studies.   Here, we share our experience of developing informatics and analytics solutions to 438 whole genomes generated from a RA clinical study.  Our learning highlights the need for s o p h i s t i c a t e d c o m p u t a t i o n a l strategies in analyzing large numbers of human genomes.

Chris HuangComputational Biologist & Biomarker Specialist Johnson & Johnson

Grant Morgan leads R&D business analytics and capacity planning at Allergan, Inc. and is the Site Head of the Bridgewater, NJ Development Center Grant has been part of the pharmaceutical industry for 15 years in scientific research and more recently business analytics, program and resource operations. He has been at Allergan for 10 years and prior to this held various positions of increasing responsibility in both small and mid-sized pharmaceutical companies.  Grant holds a BSc from University of Bradford and Ph.D. in Microbiology from The Ohio State University. He also Project Management Professional (PMP) Certified.

Using Predictive Analysis to Accurately Forecast Clinical Resource Requirements Driven by Functional Productivity

Productivity metrics of Clinical functions are being used to accurately predict forward looking clinical resource requirements across Allergan’s portfolio of Clinical studies Allergan has developed a clinical capacity resource tool (SPEAR Tool) that projects future patient enrollment and associated clinical resource type specific headcount estimates for individual studies or across region or Therapeutic Area.   In this session I will review the fundamental of this tool and the use of it as a fully i n t e g r a t e d g l o b a l r e s o u r c e management system that enables projected pipeline visualization, clinical performance tracking, clinical resource planning, portfolio long term growth and ad-hoc scenario testing

Grant MorganSr. Director, Business Analytics & CapacityAllergan

Speakers Information

Sara Rottunda is the Senior IT Program Director of the Global IT Advanced Analytics Center of Excellence at Medtronic.   The COE applies quantitative methods to diverse data sources and visualize the outcome in a way that enables leaders to derive insights and make decisions. Sara also partners with analytics thought leaders across the company to drive the collaboration and community for analytics and “big data” activities at Medtronic.   Sara has been with Medtronic for 10 years and held a variety of critical roles in Education, Quality and Supply Chain before joining Global Information Technology.   Prior to joining Medtronic, Sara held various Information Technology positions at Oracle Corporation, Cap Gemini America and Metavante Corporation.   She received her Bachelor of Science in Industrial Engineering from the University of Wisconsin Madison and has her Master of Business Administration from the Carlson School of Management at the University of Minnesota. 

Sara RottundraSnr. Director, IT, Advanced AnalyticsMedtronic

“Food Trucks Delivering Insight”. How Medtronic Global IT is Thinking Like a Restaurant to Prove the Case of Big Data & Analytics.

With the changing healthcare landscape driven by the affordable care act, big data and analytics are being viewed by the C-Suite as key enablers needed to   deliver value, and stay ahead of the competition.  A  key challenge for Information Technology organizations is how to simplify what is required to meet this vision and how best to organize the technology,  talent, and processes to execute.  In this session, you’ll hear how Medtronic, the world’s largest medical device company, has used the concept of Food Trucks and Restaurants to simplify the vision, strategy, engagement model and roadmap needed to successfully launch a Global IT Advanced Analytics Center of Excellence.   The results are leading to improved decision making for key stakeholders; including specific examples in Quality and Finance. 

Dr. Vinod Kumar is a Senior Scientific Investigator in Computational Biology, and a member of the Systematic Drug repositioning group within GlaxoSmithKline Pharmaceuticals. His current research focuses on developing computational methods for drug repurposing to help find new applications for existing drugs. Dr. Kumar is currently the editor of the “Methods in Molecular Biolog

series on biomedical literature mining. In the past, he has developed several bioinformatics data mining tools and software for pathway/network visualization and functional genomics analysis. Prior to joining GlaxoSmithKline, Dr.Kumar was an Assistant Professor of Microbiology at Thomas Jefferson University. Dr. Kumar received his PhD in Biochemistry from the Wayne State University School of Medicine and he completed his postdoctoral fellowship at the National Cancer Institute. 

Vinod KumarSenior Investigator, Computational BiologyGlaxoSmithKline

Primary care clinician, medical informatician and health services researcher with 15 years of practical experience in EHR use and implementation, research computing and integration of large datasets in support of the clinical and research enterprises. Successful track record of research with a focus on clinical trial simulation, quality measurement and exploring the contributing factors and outcomes of diagnostic and therapeutic decisions by patients and clinicians.EHR/EMR for Protocol Feasibility

Leveraging Real World Data to Re-Engineer the the Drug Development Lifecycle

This presentation will take a look at data throughout the drug development lifecycle, focusing on critiquing sources of real world data and investigating the important caveats to consider when applying real world data to research. 

Laszlo VaskoSr. Director, R&D InformationAstraZeneca

Speakers Information

Dr. Vijetha Vemulapalli has been working as a scientist at Berg LLC since she earned her Ph.D. in Computational Bioscience at University of Colorado.   Throughout her career, she has tackled complex problems using various analytics tools. She brings with her, creativity, adaptability and strong problem solving skills arising from working in diverse areas ranging from mass spectrometry data, investigation of triggers of autoimmune disease using next generation sequencing, studying genomic evolution using statistical model building, to applying artificial intelligence methods to big data in pharma. Currently she is interested in identifying, developing and optimizing meaningful computational solutions to generate recommendations for clinically relevant problems. Most recently, she has been working on identifying novel cause-and-effect relationships in healthcare big data.

Vijetha VemulapalliScientist IIBerg Pharma

Artificial Intelligence for Hypothesis Generation from Big Data

Traditional hypothesis driven science involves study design and corresponding collection of data. While this approach is important for rigorous hypothesis testing, it is limited by current knowledge and formulation of relevant hypothesis. With Artificial Intelligence (A.I.) based methods applied to big data, it is possible to (re)analyze data to identify new hypotheses that will lead to completely novel discoveries. This talk presents the use of A.I. based methods as part of the Berg Interrogative BiologyTM platform for hypothesis generation in biomarker and drug discovery using phenotypic and multi-omic data.

For the past 8 years, Kevin Gillespie has been navigating the laboratory informatics landscape at Momenta Pharmaceuticals.   Lately, he has been focusing on how Momenta can wrap its arms around the best asset it has, its data.

Big Data & the Little Guy - How a Smaller Company can Leverage Big Data

Momenta Pharmaceuticals is not a large company.  With a science staff of under 300, Momenta deals with Big (for us) Data as opposed to Big Data.   Smaller companies with fewer resources than the multi-national organizations out there often can’t approach the problem in the same way.  This talk will discuss one possible approach and how Big (for us) Data can be tackled with fewer resources and how this approach will help the thought leaders in the organization work differently.

Kevin GillespieSenior Manager, IT R&D Informatics Momenta Pharmaceuticals

Frank is the head of Celgene IT’s Global Planning & Strategy function. As part of this role, he leads the Enterprise Architecture capability and multiple IT strategic initiatives including a companywide program to advance Enterprise Information Management including the establishment of a Big Data capability.   Prior to Celgene, Frank was Chief Architect and lead the global Enterprise Architecture function for Merck.   Previously, Frank held leadership positions in consulting at KPMG Consulting and IBM Global Services where he led IT Transformations, Business Process Redesigns & Reengineering, and global CRM & Business Intelligence solution practices.

Big Data as Part of your Enterprise Information Management (EIM) Strategy

Now that Big Data is on the scene, are traditional EIM capabilities like data warehouses, data marts, and data quality needed? This discussion will highlight how Big Data supports your EIM Strategy and vice a versa.   Included in the discussion will be ways   to advance your EIM Strategy by leveraging Big Data, and how traditional analytics can be advanced by the introduction of Big Data capabilities. The contrast of Big Data from traditional analytics capabilities will be presented and   how best to determine the patterns to watch out for and when best to apply Big Data.

Frank MaltaHead of Strategic IT PlanningCelgene

The Information

For larger groups or special requests contact Pedro by calling +1 415 922 5658 or email pyiakoumi@theiegroup.com Team discounts are applicable at the point of registration only.

Ways to Register+1 415 922 5658 +1 323 446 7673 Online Reservation

Group Discount Offers3 Silver Passes: $3000 ($1000 per attendee)5 Silver Passes: $4500 ($900 per attendee)3 Gold Passes: $3900 ($1300 per attendee)5 Gold Passes: $6000 ($1200 per attendee)3 Diamond Passes: $4500 ($1500 per attendee)5 Diamond Passes: $7000 ($1400 per attendee)

Registration Pricing

Big Data & Analytics for Pharma SummitDate: November 5 & 6, 2014Location: Philadelphia, Pennsylvania Venue: SofitelAddress: 120 South 17th Street, Philadelphia, PA 19103Phone Number +1 215 569 8300

F TI L

Silver Pass

$1495Access to all sessions &

networking events7 days access to presentations from the

summit via ieOnDemand

$1295Early Bird Price(before Aug 29)

Diamond Pass

$1995Access to all sessions, networking

events, annual subscription to all content on the Big Data & Analytics channels via

ieOnDemand

$1795Early Bird Price(before Aug 29)

Gold Pass

$1795Access to all sessions, networking

events & unlimited access to presentations from the summit via

ieOnDemand

$1595Early Bird Price(before Aug 29)

1 Day Pass

$995Full access to the sessions to your chosen day of the summit, 7 days

access to presentations from the summit via ieOnDemand

7 day

nline access to event materials

On-Demand Pass

$600Unlimited access to presentations from the summit via ieOnDemand,

including presentations, interviews & the ability to contact speakers

Unlimited access to summit presentations

via ieOnDemand

NAME OF EACH ATTENDEE

TITLE OF EACH ATTENDEE DEPARTMENT

COMPANY INDUSTRY

ADDRESS CITY

STATE/PROVINCE ZIP/POSTAL CODE COUNTRY

EMAIL OF EACH ATTENDEE BUSINESS PHONE NUMBER

1. Delegate Information...

2. Pass Types...Early Bird Pass Options until Aug 29, 2014

Early Bird Silver: $1295 Attendees ____ Early Bird Gold: $1495 Attendees ____ Early Bird Diamond: $1795 Attendees ____

Regular Pass Options after Aug 29, 2014 Silver Pass: $1495 Attendees ____ Gold Pass: $1795 Attendees ____ Diamond Pass: $1995 Attendees ____

Group Discount Pass Options 3 Silver Passes $3000 ($1000 per attendee) 5 Silver Passes $4500 ($900 per attendee) 3 Gold Passes $3900 ($1300 per attendee) 5 Gold Passes $6000 ($1200 per attendee) 3 Diamond Passes $4500 ($1500 per attendee) 5 Diamond Passes $7000 ($1400 per attendee)

For larger groups or special requests contact Pedro by calling +1 (415) 922 5658 or email pyiakoumi@theiegroup.comGroup passes only available when all participants register together.

Pass Descriptions:Silver Pass: Access to all sessions & networking eventsGold Pass: Access to all sessions, networking events & unlimited access to the summit presentations via ieOnDemandDiamond Pass: Access to all sessions, networking events, annual subscription to all content on the Big Data & Analytics channels via ieOnDemand

Check (Make checks payable to The Innovation Enterprise Ltd) Invoice me

Visa Mastercard American Express Diners Club Discover

CARD NUMBER EXPIRATION DATE SECURITY NO.

CARDHOLDERS NAME CARDHOLDER’S SIGNATURE

BILLING ADDRESS -(same as above) INDUSTRY

Prices are exclusive of VAT. Places are transferable without any charge to another Summit occurring within 12 months of the original purchase. Team discounts are applicable at the point of registration only. Any cancellations within a group registration will in turn incur an increase in registration fee for the remaining group participants. Cancellations before October 04, 2014 incur an administrative charge of 50%. If you cancel your registration after October 04 2014 you will be charged the full fee. You must notify The Innovation Enterprise in writing of a cancellation, or you will be charged the full fee. The Innovation Enterprise reserve the right to make changes to the program without notice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT.

Registration FormBig Data & Analytics for Pharma SummitNovember 5 & 6, 2014 | Philadelphia, PAFor registration or more information on the program, please call Pedro on +1 (415) 922 5658, or fax this registration form to +1 (323) 446 7673

3. Payment Options...

Schedule

Networking Drinks 17.00 - 19.00

November 6

Session One 08.30 - 10.00

Coffee Break 10.00 - 10.30

Session Two 10.30 - 12.00

Lunch 12.00 - 13.30

Session Three 13.30 - 15.00

Coffee Break 15.00 - 15.30

Session Four 15.30 - 17.00

Day Two

November 5Day One 08.30

10.00

10.30

12.00

13.30

15.00

15.30

17.00

19.00

08.30

10.00

10.30

12.00

13.30

15.00

15.30

17.00

Session Five 08.30 - 10.00

Coffee Break 10.00 - 10.30

Session Six 10.30 - 12.00

Lunch 12.00 - 13.30

Session Seven 13.30 - 15.00

Coffee Break 15.00 - 15.30

Session Eight 15.30 - 17.00

Sponsors

For more information, contact us at ggodwinbrown@theiegroup.com

F TI L

Networking Drinks Sponsor

Silver Sponsor

Sponsors

For more information, contact us at ggodwinbrown@theiegroup.com

F TI L

Exhibitor Exhibitor

Exhibitor

Partnership Opportunities: Giles Godwin-Brown | ggb@theiegroup.com | +1 415 692 5498Attendee Invitation: Sean Foreman | sforeman@theiegroup.com | +1 415 692 5514

NovemberBig Data & Analyticsfor PharmaNovember 5 & 6, Philadelphia

Big Data & Marketing Innovation SummitNovember 6 & 7, Miami

Big Data for Finance November 12 & 13, Boston

Data Science Innovation Summit November 12, Chicago

Data VisualizationSummit November 12 & 13, London

Chief Data Of!cer Summit November 12 & 13, London

Big Data & Analytics Innovation SummitNovember 27 & 28, Beijing

DecemberBig Data & Analytics in Banking Summit December 3 & 4, New York

Chief Data Of!cer Summit December 3 & 4, New York

OctoberBig Data & Analytics Innovation SummitOctober 15 & 16, Dubai

JanuaryBig Data Innovation SummitJanuary 22 & 23, Las Vegas

FebruaryData Science InnovationSummitFebruary 18, San Diego

Hadoop InnovationSummitFebruary 19 & 20, San Diego

The Digital Oil!eld Innovation SummitFebruary 20 & 21, Buenos Aires

Big Data & Analytics Innovation Summit February 27 & 28, Singapore

JuneBig Data Innovation Summit June 4 & 5, Toronto

Big Data & Analytics for PharmaJune 11 & 12, Philadelphia

Open Data Innovation SummitJune 11 & 12, Boston Big Data & Analytics for Retail SummitJune 19 & 20, Chicago

MayBig Data Innovation SummitMay 14 & 15, London

Big Data & Analytics in Healthcare May 14 & 15, Philadelphia

Chief Data Of!cer SummitMay 21 & 22, San Francisco

SeptemberBig Data & Analytics Innovation SummitSeptember 17 & 18, Sydney

Data Visualization SummitSeptember 25 & 26, Boston

Big Data Innovation SummitSeptember 25 & 26, Boston

Big Data

Women

Finance

CXO Healthcare

Expected

Flagship

Government

High Tech Pharma

Oil & GasHadoop

MarchBig Data Innovation SummitMarch 27 & 28, Hong Kong

2014 Calendar

AprilBig Data Innovation SummitApril 9 & 10, Santa Clara

Big Data Infrastructure SummitApril 9 & 10, Santa Clara

Data Visualization SummitApril 9 & 10, Santa Clara

October Continued

Big Data & Analytics Innovation Summit October 16 & 17, London

JanuaryBusiness Analytics Innovation Summit January 22 & 23, Las Vegas

MarchHR & Workforce Analytics InnovationMarch 19 & 20, London

Sports Analytics Innovation SummitMarch 26 & 27, London

Predictive AnalyticsInnovation SummitMarch 27 & 28, Hong Kong

FebruaryData Science Innovation SummitFebruary 18, San Diego

Predictive Analytics Innovation Summit February 19 & 20, San Diego

Big Data & Analytics Innovation Summit February 27 & 28, Singapore

May Continued

Predictive Analytics Innovation Summit May 14 & 15, London

Digital & Web Analytics Innovation May 14 & 15, London

Big Data & Analytics in Healthcare May 14 & 15, Philadelphia

Business Intelligence Innovation Summit May 21 & 22, Chicago

Business Analytics Innovation Summit May 21 & 22, Chicago

Manufacturing Analytics Innovation SummitMay 21 & 22, Chicago

HR & Workforce Analytics Innovation May 22 & 23, Chicago

Partnership Opportunities: Giles Godwin-Brown | ggb@theiegroup.com | +1 415 692 5498Attendee Invitation: Sean Foreman | sforeman@theiegroup.com | +1 415 692 5514

SeptemberSports & Fitness Innovation SummitSeptember 10 & 11, San Francisco

Big Data & Analytics Innovation SummitSeptember 17 & 18, Sydney

Analytics

JuneBig Data & Analytics for PharmaJune 11 & 12, Philadelphia

Big Data & Analytics for Retail SummitJune 19 & 20, Chicago

Customer Analytics Innovation SummitJune 19 & 20, Chicago

MaySocial Media & Web Analytics Innovation SummitMay 1 & 2, San Francisco

Sentiment Analysis Summit May 1 & 2, San Francisco

Gaming Analytics Summit May 1 & 2, San Francisco

OctoberBig Data & Analytics Innovation Summit October 16 & 17, London

NovemberElite Minds in Sports Analytics SummitNovember 5, London

Sports TechInnovation Summit November 5 & 6, London

Big Data & Analytics for PharmaNovember 5 & 6, Philadelphia

Data Science Innovation Summit November 12, Chicago

Business Intelligence Innovation SummitNovember 12 & 13, Chicago

Predictive Analytics Innovation Summit November 12 & 13, Chicago

Social Media & Web Analytics Innovation November 12 & 13, Miami

Big Data & Analytics Innovation Summit November 27 & 28, Beijing

Retail HR

HealthcareExpected Attendees

BankingFlagship Summit

Sports Social Media

2014 Calendar

SeptemberSports Analytics Innovation September 11 & 12, Boston